| 13 December,
2003
Further on the theme of, dangerous
and useless, Statin Drugs. The following adds another downside as
if more are needed - severe nutritional cost of the drug. Apparently
pharma are well aware of this and I understand that one time one
company actually patented a combination of statin and CQ10 in a
pill but never put it on the market, unfortunately, at the moment
am not able to place the reference, however, given the marketing
shenanigans of these scoundrels it is just the thing they could
do to protect their business with disease.
Now that the cat is out of bag watch them come out with a pill
with a good dose of CQ10 and a token statin to salvage the image
of statins....
Chris Gupta
..."Statins could initiate and/or accelerate malignant growth
by a) blocking the production of Coenzyme Q10, which has been shown
to have anti-cancer effects; b) stimulating the growth of new blood
vessels that malignancies require to promote their propagation;
c) decreasing the cytotoxicity of natural killer cells; d) blocking
the production of squalene, an intermediate cholesterol metabolite
with anti-cancer activities in animal studies and currently used
as adjunctive therapy in treating cancer; e) reducing the production
of DHEA, which has been shown to have anticancer and immune stimulating
effects in experimental studies."...
High Cholesterol
May Protect Against Infections And Atherosclerosis
..."Incredibly Merck formula and Patent rights* for CQ10 were
sold to the Japanese circa 1958 as this would compete with their
blockbuster drug Diuril. Fortunately, the Japanese were able to
synthesize large quantities of this nutrient, where is it has been
used for over 30 years as an effective treatment for heart disease."...
GETTING
BOOTED FROM A DRUG INDUSTRY-SUPPORTED WEBSITE
..."Statin-induced CoQ10 depletion is well documented in animal
and human studies with detrimental cardiac consequences in both
animal models and human trials. Furthermore, this drug-induced nutrient
deficiency is dose-related and more notable in settings of pre-existing
CoQ10 deficiency such as in the elderly and in heart failure."...
CQ10
(coenzyme Q10) and Cancer
CoQ10 Depletion.
The Achilles Heel of the Statin Crusade.
Peter H. Langsjoen,
M.D., F.A.C.C., Cardiovascular Diseases. Research in Biomedical
Aspects of Coenzyme Q10. Tel (903) 595-3778, Fax (903) 595-4962
1107 Doctors Dr., Tyler, Texas 75701,USA.
www.coenzymeQ10.org
The depletion of the essential nutrient coenzyme Q10 (CoQ10) by
the increasingly popular cholesterol lowering drugs, HMG-CoA reductase
inhibitors (statins) has grown from a level of concern to one of
alarm. With ever higher statin potencies and dosages, and with a
steadily shrinking target LDL cholesterol, the prevalence and severity
of CoQ10 deficiency is increasing noticeably to the physicians in
the trenches of front line patient care. An estimated 36 million
Americans are now candidates for statin drug therapy.
CoQ10 serves as the coenzyme for mitochondrial enzyme complexes
I, II and III and is essential for mitochondrial ATP production.
CoQ10 is also a clinically relevant fat-soluble antioxidant and
is the only fat soluble antioxidant that is known to be synthesized
de novo. It is found normally in the diet, predominantly in organ
meats and is biosynthesized in all cells with peak capabilities
in late teens and early twenties with a gradual age-related decline
in blood and tissue CoQ10 levels after the age of 30 years.
Statin-induced CoQ10 depletion has been documented in 15 animal
studies in six different animal species and has been shown to correlate
with decreased ATP production, increased ischemia reperfusion injury,
skeletal muscle injury and increased mortality.
There are 15 published trials on statin-induced CoQ10 depletion
in humans. Of these 15 trials, nine were controlled trials, eight
of which documented significant CoQ10 depletion. Statin-induced
CoQ10 depletion has been shown to be associated with a fall in left
ventricular function, an elevation of lactate to pyruvate ratio
and an enhancement of LDL cholesterol oxidation. The current data
on diastolic dysfunction further confirms the clinical importance
of this drug-nutrient interaction.
Statin-induced CoQ10 depletion is well documented in animal and
human studies with detrimental cardiac consequences in both animal
models and human trials. Furthermore, this drug-induced nutrient
deficiency is dose-related and more notable in settings of pre-existing
CoQ10 deficiency such as in the elderly and in heart failure. Finally,
statin-induced CoQ10 deficiency is completely preventable with supplemental
CoQ10 with no adverse impact on the cholesterol lowering or anti-inflammatory
properties of the statin drugs.
We are currently in the midst of a congestive heart failure epidemic
in the United States, the cause or causes of which are unclear.
As physicians, it is our duty to be absolutely certain that we are
not inadvertently doing harm to our patients by creating a wide-spread
deficiency of a nutrient critically important for normal heart function.
See also:
Coenzyme
Q10
Statin
Drugs & Breast Cancer
Statin
Drugs & Memory Loss
|
